Erasca shares plunge 48% after patient death in cancer drug trial

6 articles · Updated · The Wall Street Journal · Apr 28

Erasca lost about $2.7 billion in market value after disclosing a patient died from lung inflammation during a pancreatic cancer trial.
The company reported its drug shrank tumors in 41% of Chinese patients but only 14% in the U.S., raising concerns about trial differences and incomplete safety data.
Analysts flagged the varied data presentation as a red flag, while earlier reports noted additional pressure from patent infringement claims and underwhelming clinical results compared to competitors.

With its lead drug faltering, can Erasca survive the onslaught from its rival?

Amid conflicting data, which company is truly winning the cancer drug race?

A patient died after taking the drug. Was it an isolated tragedy or a major red flag?

What makes one experimental drug a 'paradigm shift' while its rival's fails?

Is the trade secret lawsuit a valid IP claim or a tactic to crush a competitor?